A great global concern is currently focused on the coronavirus disease 2019 (COVID-19) pandemic and its associated morbidities. The goal of this study was to determine the frequency of newly diagnosed diabetes mellitus (DM) and its different types among COVID-19 patients, and to check the glycemic control in diabetic cases for three months. After excluding known cases of DM, 570 patients with confirmed COVID-19 were studied. All participants were classified as non-diabetic or newly discovered diabetic. According to hemoglobin A1c (HbA1c) and fasting insulin, newly discovered diabetic patients were further classified into pre-existing DM, new-onset type 1 DM, and new-onset type 2 DM. Glycemic control was monitored for three months in newly diagnosed diabetic patients. DM was diagnosed in 77 patients (13.5%); 12 (2.1%) with pre-existing DM, 7 (1.2%) with new-onset type 1 DM, and 58 (10.2%) with new-onset type 2 DM. Significantly higher rates of severe infection and mortality (p < 0.001 and p = 0.046) were evident among diabetic patients. Among survived diabetic patients (n = 63), hyperglycemia and the need for anti-diabetic treatment persisted in 73% of them for three months. COVID-19 was associated with a new-onset of DM in 11.4% of all participants and expression of pre-existing DM in 2.1% of all participants, both being associated with severe infection. COVID-19 patients with newly diagnosed diabetes had high risk of mortality. New-onset DM persisted for at least three months in more than two-thirds of cases.

Introduction: Omentin-1, is an adipokine, inhibits TNF-induced inflammation of vascular smooth muscle cells, so its decreased levels in plasma of patients with coronary artery disease (CAD), indicated that omentin-1 may also be involved in the occurrence of CAD. Objective: Study the alternation of plasma levels of omentin-1 and chemerin in patients with coronary artery diseases. Patients and methods: This case-control study was carried out on 120 patients with coronary artery disease and 50 healthy volunteers, in the period from January 2018 to June 2019, divided into control group: 50 healthy volunteers, stable angina pectoris group: 60 cases, acute coronary syndrome (ACS) group: 60 cases, which were subclassified into; (a) 20 unstable angina (USA) cases; (b) 20 segment elevation myocardial infarction (STEMI) cases; (c) 20 non ST segment elevation myocardial infarction (NSTEMI) cases. Results: There was a highly significant difference between the studied groups in hsCRP, omentin-1 and chemerin levels with significant difference in SA group and ACS groups compared to control group. Regarding acute coronary syndrome (ACS) groups, there was significant difference in hsCRP between USA and infarction groups. Chemerin showed significant difference between USA and STEMI and USA and Non STE MI. While omentin-1 showed no significant difference between ACS subgroups. Regarding CAD without DM type2 and CAD with DM type2. There was high statistical significant difference between the groups as regarding FBG, HbA1c, total cholesterol (T. Chol), HDL-C, LDL-C, hsCRP, chemerin and omentin-1. Conclusion: increasing total cholesterol, triglycerides, LDL-C, high-sensitivity C-reactive protein (hsCRP) and chemerin. Decreasing HDL-C and Omentin-1 are independent predictors of CAD in type 2 diabetic patients.